Niraxostat
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 341086

CAS#: 206884-98-2

Description: Niraxostat, also known as Y-700 and Piraxostat, is a novel inhibitor of xanthine oxidase. Y-700 suppresses the development of colon aberrant crypt foci and cell proliferation in 1,2-dimethylhydrazine-treated mice. Y-700 is a promising candidate for the treatment of hyperuricemia and other diseases in which XOR may be involved. Y-700 showed high oral bioavailability, which is predominantly eliminated via the liver unlikely to allopurinol.

Chemical Structure

img
Niraxostat
CAS# 206884-98-2
Product data Instruction

Theoretical Analysis

MedKoo Cat#: 341086
Name: Niraxostat
CAS#: 206884-98-2
Chemical Formula: C16H17N3O3
Exact Mass: 299.13
Molecular Weight: 299.330
Elemental Analysis: C, 64.20; H, 5.72; N, 14.04; O, 16.03

Price and Availability

Size Price Availability Quantity
5mg USD 345 2 Weeks
25mg USD 1100 2 Weeks
Bulk inquiry

Synonym: Niraxostat; Y 700; Y-700; Y700; Piraxostat;

IUPAC/Chemical Name: 1-(3-cyano-4-(neopentyloxy)phenyl)-1H-pyrazole-4-carboxylic acid

InChi Key: AETHRPHBGJAIBT-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H17N3O3/c1-16(2,3)10-22-14-5-4-13(6-11(14)7-17)19-9-12(8-18-19)15(20)21/h4-6,8-9H,10H2,1-3H3,(H,20,21)

SMILES Code: O=C(C1=CN(C2=CC=C(OCC(C)(C)C)C(C#N)=C2)N=C1)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:
Product Data
Instruction:
View handling instruction
Biological target: Niraxostat is a biochemical.
In vitro activity: TBD
In vivo activity: TBD

Preparing Stock Solutions

The following data is based on the product molecular weight 299.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: TBD
In vitro protocol: TBD
In vivo protocol: TBD

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Fukunari A, Okamoto K, Nishino T, Eger BT, Pai EF, Kamezawa M, Yamada I, Kato N. Y-700 [1-[3-Cyano-4-(2,2-dimethylpropoxy)phenyl]-1H-pyrazole-4-carboxylic acid]: a potent xanthine oxidoreductase inhibitor with hepatic excretion. J Pharmacol Exp Ther. 2004 Nov;311(2):519-28. doi: 10.1124/jpet.104.070433. Epub 2004 Jun 9. PMID: 15190124.


2: Hashimoto T, Fukunari A, Yamada I, Yanaka N, Chen D, Kato N. Y-700, a novel inhibitor of xanthine oxidase, suppresses the development of colon aberrant crypt foci and cell proliferation in 1,2-dimethylhydrazine-treated mice. Biosci Biotechnol Biochem. 2005 Jan;69(1):209-11. doi: 10.1271/bbb.69.209. PMID: 15665488.


3: Yamada I, Fukunari A, Osajima T, Kamezawa M, Mori H, Iwane J. Pharmacokinetics/pharmacodynamics of Y-700, a novel xanthine oxidase inhibitor, in rats and man. Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(8-9):1123-5. doi: 10.1081/NCN-200027384. PMID: 15571214.


4: Tiu RV, Mountantonakis SE, Dunbar AJ, Schreiber MJ Jr. Tumor lysis syndrome. Semin Thromb Hemost. 2007 Jun;33(4):397-407. doi: 10.1055/s-2007-976175. PMID: 17525897.


5: Sai Y, Kato Y, Nakamura K, Kato S, Nishimura T, Kubo Y, Tamai I, Yang S, Hu Z, Yamada I, Tsuji A. Carrier-mediated hepatic uptake of a novel nonrenal excretion type uric acid generation inhibitor, Y-700. J Pharm Sci. 2006 Feb;95(2):336-47. doi: 10.1002/jps.20540. PMID: 16369928.


6: Su X, Li W, Sun H, Wang J, Hu S, Yuan F, Zhang D, Wang B. Porous carbon- confined Co x S y nanoparticles derived from ZIF-67 for boosting lithium-ion storage. RSC Adv. 2022 Jan 4;12(2):939-946. doi: 10.1039/d1ra08581f. PMID: 35425149; PMCID: PMC8978921.


7: Bomalaski JS, Clark MA. Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase. Curr Rheumatol Rep. 2004 Jun;6(3):240-7. doi: 10.1007/s11926-004-0075-3. PMID: 15134605.


8: Zhang TJ, Wu QX, Li SY, Wang L, Sun Q, Zhang Y, Meng FH, Gao H. Synthesis and evaluation of 1-phenyl-1H-1,2,3-triazole-4-carboxylic acid derivatives as xanthine oxidase inhibitors. Bioorg Med Chem Lett. 2017 Aug 15;27(16):3812-3816. doi: 10.1016/j.bmcl.2017.06.059. Epub 2017 Jun 23. PMID: 28693909.


9: Schwendicke F, Stolpe M, Meyer-Lueckel H, Paris S. Detecting and treating occlusal caries lesions: a cost-effectiveness analysis. J Dent Res. 2015 Feb;94(2):272-80. doi: 10.1177/0022034514561260. Epub 2014 Dec 10. PMID: 25503613; PMCID: PMC4438735.


10: Shahraki A, Fukunari A, Stone TW. The mechanism of inhibition by xanthine of adenosine A1-receptor responses in rat hippocampus. Neurosci Lett. 2004 Jul 29;365(3):162-6. doi: 10.1016/j.neulet.2004.04.075. PMID: 15246540.